———————————————————
Pharmacy benefit managers quietly shape what you pay for prescriptions, and CVS Caremark PBM is the largest of them all. Processing over 2 billion adjusted claims annually, CVS Caremark sits at the center of a complex system connecting insurers, drug manufacturers, pharmacies, and patients. Understanding how this company operates helps you make sense of your prescription costs and coverage decisions. It is also worth noting up front that PBMs are the subject of an active policy debate – one that reached a notable milestone in 2026 – and there are competing, good-faith views about whether they lower or raise what patients ultimately pay. This explainer aims to lay out the mechanics neutrally.
What Does CVS Caremark Do as a PBM?
A pharmacy benefit manager negotiates drug prices, builds formularies, processes claims, and manages pharmacy networks on behalf of health plans and employers. CVS Caremark performs all of these functions at enormous scale. When your employer selects CVS Caremark, the company helps determine which drugs your plan covers, what tier they sit on, and how much you pay at the counter.
The company also runs a mail-order pharmacy operation, manages specialty-drug programs, and provides clinical services such as medication therapy management. For a foundational explanation of what PBMs are and why they matter, see our PBM explainer.
How CVS Caremark Builds Its Formulary
Formulary design is where PBMs exert the most influence over your healthcare costs. CVS Caremark’s Pharmacy and Therapeutics (P&T) committee – composed of physicians and pharmacists – evaluates drugs based on clinical effectiveness, safety, and cost. The committee places drugs into tiers, with lower tiers generally carrying lower copays.
Here is where business meets medicine. Drug manufacturers offer rebates to PBMs in exchange for favorable formulary placement. A brand-name drug maker might pay a sizable rebate off the list price to secure preferred status over a competitor’s product. According to KFF and other analysts, aggregate rebates across the PBM industry have run into the many tens of billions of dollars annually, and total gross-to-net reductions on brand drugs are large. Exactly how much of that value reaches patients at the counter is central to the policy debate.
Critics argue this system can prioritize rebate revenue over the lowest possible cost to patients, and that rebates tied to list price create incentives to favor higher-list-price drugs. CVS Caremark counters that rebates reduce premiums and overall plan costs, even if they do not always translate directly to lower copays at the pharmacy counter. Both framings appear in the ongoing reform discussion.
The Vertical Integration Debate
What sets CVS Caremark PBM apart from some competitors is its integration with CVS Health’s other businesses. CVS Health owns CVS Pharmacy (the retail chain), CVS Caremark (the PBM), CVS Specialty (specialty pharmacy), Aetna (health insurance), and retail clinics. This vertical integration means a single parent company touches the insurance, the benefit management, and much of the pharmacy dispensing.
Proponents say integration creates efficiencies, with data flowing between the insurer and the pharmacy without the friction of separate companies. Critics, including the FTC, have raised concerns about potential conflicts of interest – for example, incentives to steer prescriptions toward affiliated pharmacies. These are contested questions, and the companies dispute several of the characterizations. The direction of policy, however, has clearly been toward more scrutiny and disclosure.
Impact on Independent Pharmacies
Independent pharmacies have been particularly vocal about PBM practices. According to the National Community Pharmacists Association, many independent pharmacies report that PBM reimbursement rates can fall below their acquisition costs for certain medications. Related to this is “spread pricing,” in which a PBM charges a plan more for a drug than it reimburses the pharmacy and keeps the difference. Reform efforts, discussed below, increasingly target spread pricing and push toward acquisition-cost-based reimbursement for pharmacies.
How CVS Caremark Affects Your Out-of-Pocket Costs
Your experience with CVS Caremark depends heavily on your specific plan design. Two members with CVS Caremark benefits can have very different formularies, copay structures, and network restrictions based on what their employers negotiated.
Several factors determine your cost. Formulary tier placement sets the base copay or coinsurance. Network status matters too – filling at a preferred pharmacy may carry a lower copay than using a non-preferred one. Mail-order prescriptions through CVS Caremark’s mail service are often the lowest-cost route for 90-day maintenance supplies. Prior authorization, step therapy, and quantity limits add another layer: these utilization-management tools control spending but can delay access to medications your doctor prescribes. If you hit a coverage wall, understanding the appeals process is essential.
Recent Regulatory Scrutiny and the 2026 FTC Settlements
PBMs have faced intense regulatory attention. The FTC launched a major study of PBM practices in 2022 and released interim reports in 2024 and 2025 that raised concerns about rebate retention, formulary design, vertical integration, and effects on drug affordability – findings the PBMs disputed in part. In September 2024, the FTC also brought an administrative case against the three largest PBMs – Caremark, Express Scripts, and OptumRx – and their affiliated group purchasing organizations, alleging that rebate practices around insulin inflated list prices and shifted costs to some patients.
That litigation resolved through settlements in 2026. The FTC reached a settlement with Express Scripts in February 2026, and then with CVS Caremark in mid-2026, with OptumRx also agreeing to terms. According to the FTC and company statements, the agreements focus on measures such as promoting point-of-sale rebate pass-through so savings can reach members at the counter, moving away from tying manufacturer compensation to list price, giving plan sponsors options to avoid spread pricing, and transitioning toward acquisition-cost-based reimbursement for independent pharmacies (with certain provisions phasing in over the following years). The FTC framed the settlements as delivering billions of dollars in projected consumer savings over a decade; the companies framed them as advancing transparency and affordability while contesting some of the agency’s underlying claims. The bottom line for readers: reform is moving, but its real-world effect on individual copays will unfold over time and will depend heavily on how plan sponsors adopt the new options.
At the state level, more than 40 states have enacted some form of PBM regulation, according to the National Conference of State Legislatures, ranging from licensing requirements to rebate-transparency mandates. Federal legislation targeting PBM practices has also been proposed repeatedly with bipartisan interest. This remains an active, evolving area of policy, so specifics may change after publication.
For a broader view of how PBM regulation fits into the healthcare landscape, explore our healthcare policy guide.
CVS Caremark PBM vs. Competitors
Three PBMs dominate the US market: CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group). Together they administer roughly 80% of US prescription claims. Each follows a broadly similar business model, but their pharmacy networks, formularies, and plan designs differ.
CVS Caremark’s primary competitive advantage is its retail pharmacy footprint, giving members extensive in-person access. Express Scripts counters with a broad network of partner pharmacies, and OptumRx leverages UnitedHealth’s insurance scale. For plan sponsors choosing among these PBMs, the decision often comes down to network fit, pricing transparency, and clinical-program quality – factors that the new transparency commitments may make easier to compare over time.
Frequently Asked Questions
Is CVS Caremark the same as CVS Pharmacy?
No. CVS Caremark is the pharmacy-benefit-management division that handles insurance claims, formularies, and drug pricing. CVS Pharmacy is the retail chain where you pick up prescriptions. Both are owned by CVS Health, but they serve different functions.
Why did my medication cost change with CVS Caremark?
Formulary changes, tier reassignments, and manufacturer price changes can all affect your costs. CVS Caremark updates its formulary periodically, and your plan sponsor (usually your employer) may also change plan design at renewal. Check your current formulary online for the latest tier information.
Can I appeal a CVS Caremark coverage denial?
Yes. CVS Caremark has a formal appeals process. Your doctor can submit a coverage-determination request, and you have the right to appeal a denial. For Medicare Part D plans, the appeals process follows federal guidelines with specific timelines for standard and expedited reviews.
How do I find out if CVS Caremark manages my benefits?
Check your prescription benefit card. If it shows the CVS Caremark name or lists Caremark as the PBM, your benefits are managed by CVS Caremark. You can also call the number on the back of your card to confirm. See our CVS Caremark card guide for more details.
Did the FTC settlement lower my drug prices?
Not automatically. The 2026 settlements set up mechanisms – like point-of-sale rebate pass-through and fairer pharmacy reimbursement – that could reduce some patients’ costs over time, with parts phasing in over subsequent years. Whether you see lower prices depends on how your specific plan sponsor adopts these options.
TL;DR: CVS Caremark is the largest US PBM, and it influences your drug costs through formularies, tiers, rebates, and pharmacy networks. Rebates and spread pricing sit at the heart of a long-running policy debate, which produced FTC settlements with all three major PBMs in 2026 aimed at more transparency and point-of-sale savings. The practical takeaways for members are unchanged: know your formulary, use preferred and mail-order pharmacies for maintenance drugs, and appeal denials. This is general information about how the system works, not personalized financial, legal, or medical advice.
What This Means for You
The CVS Caremark PBM machine is complex, but the practical takeaways are simple. Know your formulary. Use preferred pharmacies. Consider mail order for maintenance medications. And if you face a coverage denial, appeal it, because a meaningful share of appeals result in reversed decisions. Keep an eye on the evolving policy landscape, too – the 2026 reforms may gradually change how rebate savings reach patients. The system rewards informed members who understand the levers that control their prescription costs. For a deeper dive into PBM mechanics, read our guide on PBMs in healthcare.
Sources
- Federal Trade Commission – PBM interim staff reports (2024-2025), the 2024 insulin case, and the 2026 settlements with Express Scripts, Caremark, and OptumRx
- KFF – analysis of drug rebates and the PBM market
- National Community Pharmacists Association (NCPA) – independent-pharmacy reimbursement concerns
- National Conference of State Legislatures (NCSL) – state PBM regulation
- CVS Health – corporate communications on the FTC agreement